Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at selvom Tasigna ikke var blevet direkte sammenlignet med andre typer behandling, var virkningen af lægemidlet blevet tilstrækkeligt påvist og svarede til virkningen af andre lægemidler i samme klasse.
The Committee for Medicinal Products for Human Use (CHMP) concluded that, even though it was not directly compared to any other treatment, the effectiveness of Tasigna had been demonstrated sufficiently and was the same as that of another medicine in the same class.